Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Myelomonocytic, Chronic 1Hemangiosarcoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

trametinib 2cabozantinib 2Magnetic Resonance Spectroscopy 2spartalizumab 1omipalisib 1dabrafenib 1Specimen Handling 1Sodium Iodide 1Nivolumab 1Ipilimumab 1Iodine-131 1Iodine-124 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Follicular × spartalizumab × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡